AR074688A1 - Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. - Google Patents
Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.Info
- Publication number
- AR074688A1 AR074688A1 ARP090104911A ARP090104911A AR074688A1 AR 074688 A1 AR074688 A1 AR 074688A1 AR P090104911 A ARP090104911 A AR P090104911A AR P090104911 A ARP090104911 A AR P090104911A AR 074688 A1 AR074688 A1 AR 074688A1
- Authority
- AR
- Argentina
- Prior art keywords
- piperidin
- nhet
- nhet1
- hal
- nor2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la fórmula (1) en donde R1 es Ar, Het, A, OR2, O[C(R2)2]nAr, O[C(R2)2]nHet, N(R2)2, NR2[C(R2)2]nAr o NR2[C(R2)2]nHet; R2 es H o A'; R3, R3' son, en cada caso de modo independiente entre sí, H, Hal, A, OR2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, SO2N(R2)2 o S(O)mA, Y es [C(R2)2]nNR2COZ, [C(R2)2]nNR2COHet1, [C(R2)2]nCyc[C(R2)2]nN(R2)2, [C(R2)2]nCyc[C(R2)2]nOR2, [C(R2)2]nCyc[C(R2)2]nHet1, [C(R2)2]n-C(CH2)-((CH2)p)-[C(R2)2]nN(R2)2, [C(R2)2]n-C(CH2-(CH2)p)[C(R2)2]nOR2, [C(R2)2]n-C(CH2-(CH2)p)-[C(R2)2]nHet, [C(R2)2]nHet2, [C(R2)2]nCR2(NR2)2COOR2, [C(R2)2]nNR2CO[C(R2)2]nNR2COA, [C(R2)2]nNR2COOA, [C(R2)2]nCO-NR2-A, [C(R2)2]nCO-NR2-[C(R2)2]nHet1, [C(R2)2]nCONH2, [C(R2)2]nCONHA, [C(R2)2]nCONA2, [C(R2)2]nCO-NR2-[C(R2)2]nN(R2)2 o COOA; ; Z es CR2(NR2)2CR2(OR2)A, Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Hal, A, [C(R2)2]nOR2, [C(R2)2]nN(R2)2, SR2, NO2, CN, CO-OR2, CON(R2)2, NR2COA, NR2SO2A, SO2N(R2)2, S(O)mA, CO-Het, Het, O[C(R2)2]nN(R2)2, O[C(R2)2]nHet, NHCOOA, NHCON(R2)2, NHCOO[C(R2)2]nN(R2)2, NHCOO[C(R2)2]nHet, NHCONH[C(R2)2]nN(R2)2, NHCONH[C(R2)2]nHet, OCONH[C(R2)2]nN(R2)2, OCONH[C(R2)2]nHet, CONR2[C(R2)2]nN(R2)2, CONR2[C(R2)2]nHet, y/o COA, Het es un heterociclo mono-, bi- o tricíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, [C(R2)2]nOR2, [C(R2)2]n(R2)2, SR2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, SO2N(R2)2, S(O)mA, CO-Het1, [C(R2)2]nHet1, O[C(R2)2]nN(R2)2, O[C(R2)2]nHet1, NHCOOA, NHCON(R2)2, NHCOO[C(R2)2]nN(R2)2, NHCOO[C(R2)2]nHet1, NHCONH[C(R2)2]nN(R2)2, NHCONH[C(R2)2]nHet1, OCONH[C(R2)2]nN(R2)2, OCONH[C(R2)2]nHet1, CO-Het1, CHO, COA, =S, =NH, =NA y/u =O (oxígeno del carbonilo), Het1 es un heterociclo saturado monocíclico con 1 a 2 átomos de N y/u O, que puede estar mono- o disustituido con A, OA, OH, COOH, COOA, Hal y/u =O (oxígeno del carbonilo), Het2 es 2-metoxicarbonil-pirrolidin-4-ilo, 2-carboxi-pirrolidin-4-ilo, 1-ciclopropilmetil-piperidin-4-ilo, piperidin-4-ilo, morfolin-2-o 4-ilo, 1-isopropil-piperidin-4-ilo, 1-metil-piperidin-4-ilo, 4-piperazinilo, 1-metil-pirrolidin-2-ilo, 1-ter.-butoxicarbonil-piperidin-4-ilo, 1-etil-piperidin-2-ilo, 1-(2-metoxi-etil)-piperidin-4-ilo, 1-[2-(N,N-dimetilamino)-etil]-piperidin-4-ilo, 1,2,2,6,6-pentametil-piperidin-4-ilo, 1-aza-biciclo[2,2,2]oct-3-ilo, tetrahidropiran-4-ilo, 1-formil-piperidin-4-ilo o 1-metil-1-oxi-piperidin-4-ilo, A es alquilo no ramificado o ramificado C1-10, en donde 1-7 átomos de H pueden estar reemplazados por F, y/o en donde uno o dos grupos CH2 no adyacentes pueden estar reemplazados por O, NH, S, SO, SO2 y/o grupos CH=CH, o es alquilo cíclico C3-7, A' es alquilo no ramificado o ramificado C1-6 en donde 1-5 átomos de H pueden estar reemplazados por F; CyC es cicloalquileno C3-7; Hal es F, Cl, Br o I; m es 0, 1 o 2, n es 1, 2, 3 o 4, p es 1, 2, 3, 4, o 5; así como sus sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la Met-quinasa, y pueden utilizarse, por ejemplo, para el tratamiento de tumores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008062826A DE102008062826A1 (de) | 2008-12-23 | 2008-12-23 | Pyridazinonderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074688A1 true AR074688A1 (es) | 2011-02-02 |
Family
ID=41628227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104911A AR074688A1 (es) | 2008-12-23 | 2009-12-16 | Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8637518B2 (es) |
EP (1) | EP2367815B1 (es) |
JP (1) | JP5592395B2 (es) |
KR (1) | KR20110098854A (es) |
CN (1) | CN102264727B (es) |
AR (1) | AR074688A1 (es) |
AU (1) | AU2009331991B2 (es) |
BR (1) | BRPI0923497A2 (es) |
CA (1) | CA2747863C (es) |
CY (1) | CY1116191T1 (es) |
DE (1) | DE102008062826A1 (es) |
DK (1) | DK2367815T3 (es) |
EA (1) | EA201100966A1 (es) |
ES (1) | ES2532139T3 (es) |
HR (1) | HRP20150375T1 (es) |
HU (1) | HUE025138T2 (es) |
MX (1) | MX2011006652A (es) |
PL (1) | PL2367815T3 (es) |
PT (1) | PT2367815E (es) |
SI (1) | SI2367815T1 (es) |
WO (1) | WO2010072296A1 (es) |
ZA (1) | ZA201105440B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
MX2015007921A (es) * | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
SG11201506100XA (en) * | 2013-02-07 | 2015-09-29 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての置換複素環 |
CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
HUE051734T2 (hu) * | 2016-10-27 | 2021-03-29 | Fujian Cosunter Pharmaceutical Co Ltd | Piridon-vegyület, mint C-Met inhibitor |
US11465986B2 (en) | 2018-04-26 | 2022-10-11 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor |
CN108752322A (zh) * | 2018-09-12 | 2018-11-06 | 广州新民培林医药科技有限公司 | 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用 |
WO2020191056A1 (en) * | 2019-03-20 | 2020-09-24 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
WO2022063869A2 (en) * | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
CN114736191B (zh) * | 2022-04-01 | 2023-08-08 | 上海工程技术大学 | 特普替尼中间体及其制备方法和应用 |
CN115583939A (zh) * | 2022-11-04 | 2023-01-10 | 苏州莱安医药化学技术有限公司 | 一种特泊替尼中间体的合成方法 |
CN116768868B (zh) * | 2023-08-15 | 2023-12-08 | 云南省药物研究所 | 一种哒嗪酮硫代衍生物及其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
IL115889A0 (en) | 1994-11-14 | 1996-01-31 | Rohm & Haas | Pyridazinones and their use as fungicides |
US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DE19604388A1 (de) | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
PT1043317E (pt) | 1997-11-19 | 2009-05-11 | Kowa Co | Novos derivados de piridazina e fármacos que os contêm como ingrediente activo |
TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
MXPA04003668A (es) | 2001-10-31 | 2004-07-22 | Merck Patent Gmbh | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
DE102005055354A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
BRPI0923480B8 (pt) * | 2008-12-22 | 2021-05-25 | Merck Patent Gmbh | formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etóxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona, seus processos de fabricação, composição farmacêutica, medicamento, e kit |
WO2010113986A1 (ja) * | 2009-03-30 | 2010-10-07 | 住友化学株式会社 | ピリダジノン化合物の有害節足動物防除用途 |
-
2008
- 2008-12-23 DE DE102008062826A patent/DE102008062826A1/de not_active Withdrawn
-
2009
- 2009-11-24 CN CN200980152038.8A patent/CN102264727B/zh active Active
- 2009-11-24 ES ES09759895.7T patent/ES2532139T3/es active Active
- 2009-11-24 AU AU2009331991A patent/AU2009331991B2/en active Active
- 2009-11-24 DK DK09759895T patent/DK2367815T3/en active
- 2009-11-24 SI SI200931166T patent/SI2367815T1/sl unknown
- 2009-11-24 EA EA201100966A patent/EA201100966A1/ru unknown
- 2009-11-24 MX MX2011006652A patent/MX2011006652A/es not_active Application Discontinuation
- 2009-11-24 US US13/141,400 patent/US8637518B2/en active Active
- 2009-11-24 WO PCT/EP2009/008360 patent/WO2010072296A1/de active Application Filing
- 2009-11-24 CA CA2747863A patent/CA2747863C/en active Active
- 2009-11-24 PT PT97598957T patent/PT2367815E/pt unknown
- 2009-11-24 EP EP09759895.7A patent/EP2367815B1/de active Active
- 2009-11-24 HU HUE09759895A patent/HUE025138T2/en unknown
- 2009-11-24 KR KR1020117017357A patent/KR20110098854A/ko not_active Application Discontinuation
- 2009-11-24 BR BRPI0923497A patent/BRPI0923497A2/pt not_active IP Right Cessation
- 2009-11-24 PL PL09759895T patent/PL2367815T3/pl unknown
- 2009-11-24 JP JP2011542689A patent/JP5592395B2/ja active Active
- 2009-12-16 AR ARP090104911A patent/AR074688A1/es unknown
-
2011
- 2011-07-22 ZA ZA2011/05440A patent/ZA201105440B/en unknown
-
2015
- 2015-03-31 HR HRP20150375TT patent/HRP20150375T1/hr unknown
- 2015-04-09 CY CY20151100345T patent/CY1116191T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP5592395B2 (ja) | 2014-09-17 |
AU2009331991A1 (en) | 2011-08-11 |
US20110257181A1 (en) | 2011-10-20 |
MX2011006652A (es) | 2011-07-12 |
DK2367815T3 (en) | 2015-03-09 |
CN102264727B (zh) | 2014-11-05 |
EP2367815B1 (de) | 2015-01-14 |
DE102008062826A1 (de) | 2010-07-01 |
BRPI0923497A2 (pt) | 2019-09-24 |
CN102264727A (zh) | 2011-11-30 |
CY1116191T1 (el) | 2017-02-08 |
CA2747863A1 (en) | 2010-07-01 |
SI2367815T1 (sl) | 2015-05-29 |
AU2009331991B2 (en) | 2015-10-22 |
EP2367815A1 (de) | 2011-09-28 |
JP2012513418A (ja) | 2012-06-14 |
ES2532139T3 (es) | 2015-03-24 |
KR20110098854A (ko) | 2011-09-01 |
CA2747863C (en) | 2016-08-23 |
PL2367815T3 (pl) | 2015-04-30 |
EA201100966A1 (ru) | 2012-01-30 |
PT2367815E (pt) | 2015-02-20 |
WO2010072296A1 (de) | 2010-07-01 |
HUE025138T2 (en) | 2016-03-29 |
HRP20150375T1 (hr) | 2015-05-22 |
US8637518B2 (en) | 2014-01-28 |
ZA201105440B (en) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074688A1 (es) | Derivados de piridazinona, procedimiento para prepararlos, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
AR066543A1 (es) | Derivados de piridazinona | |
AR071208A1 (es) | Derivados de piridazinona | |
AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
AR083670A1 (es) | DERIVADOS DE 7-([1,2,3]TRIAZOL-4-IL)-PIRROLO[2,3-b]PIRAZINA UTILES COMO INHIBIDORES DE LA PROLIFERACION CELULAR, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y PROCEDIMIENTO PARA PREPARARLOS | |
AR073055A1 (es) | Derivados biciclicos de triazol | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
AR075122A1 (es) | Derivados de piridazinona | |
PE20141370A1 (es) | Inhibidores de quinasa | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR092211A1 (es) | Derivados de hidropirrolopirrol | |
AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
AR082109A1 (es) | Derivados de bipiridilo | |
AR094214A1 (es) | Inhibidores de la quinasa que regula la señal de la apoptosis | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
AR089945A1 (es) | DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe | |
AR067081A1 (es) | Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales. | |
AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
AR077567A1 (es) | Derivados de aminopiridina | |
AR077488A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de autotaxina, medicamentos que los contienen y uso de los mismos para el tratamiento y/o prevencion de cancer y enfermedades tumorales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |